News
WCLC: Amgen eyes first-line use for KRAS drug Lumakras
Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is und
